MRNA
Moderna, Inc.
NASDAQ · USHealthcareBiotechnology
$59.49-3.77%
Price as of Jul 20, 2026
MRNA financials
Moderna, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $1.9B | $3.2B | $6.8B | $18.9B |
| Cost of revenue | $868.0M | $1.5B | $4.7B | $5.4B |
| Gross profit | $1.1B | $1.7B | $2.2B | $13.5B |
| Operating expenses | $4.2B | $5.7B | $6.4B | $4.0B |
| Operating income | -$3.1B | -$3.9B | -$4.2B | $9.4B |
| Net income | -$2.8B | -$3.6B | -$4.7B | $8.4B |
| EBITDA | -$2.6B | -$3.4B | -$3.3B | $10.0B |
| Basic EPS | $-7.26 | $-9.27 | $-12.34 | $21.26 |
| Diluted EPS | $-7.26 | $-9.27 | $-12.34 | $20.10 |
| Balance sheet | ||||
| Cash & equivalents | $2.6B | $1.9B | $2.9B | $3.2B |
| Total assets | $12.3B | $14.1B | $18.4B | $25.9B |
| Total liabilities | $3.7B | $3.2B | $4.6B | $6.7B |
| Stockholders’ equity | $8.7B | $10.9B | $13.9B | $19.1B |
| Total debt | $1.9B | $747.0M | $1.2B | $1.2B |
| Net debt | -$679.0M | -$1.2B | -$1.7B | -$2.0B |
| Cash flow | ||||
| Operating cash flow | -$1.9B | -$3.0B | -$3.1B | $5.0B |
| Capital expenditure | -$192.0M | -$1.1B | -$707.0M | -$400.0M |
| Free cash flow | -$2.1B | -$4.1B | -$3.8B | $4.6B |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | -$1.2B | -$3.3B |